



**EVITRADE
Health
Systems
Corporation**

EVITRADE Health Systems Corporation

EVITRADE Health Systems Announces Private Placement with Minimum CDN \$500,000 Allocated

VANCOUVER, BC, Monday October 3, 2016 – EVITRADE Health Systems Corp. (CSE:EVA, OTCQB: AXHLD) (the “Company” or “EVITRADE”) today announced that it intends to raise gross proceeds of a minimum CDN \$500,000, and up to CDN \$1,000,000 through a non-brokered private placement of common shares or convertible debt convertible into shares of the Company (the “Shares”) at a price of \$2.50 per common share (the "Offering"). A finder’s fee of up to 7% cash may be paid on portions of the gross proceeds. The Company is pleased to announce that the minimum amount of CDN\$500,000 has already been allocated.

Proceeds from the Offering are intended to be used as working capital to support commercialization of the Company’s services, with emphasis on the telehealth platform for consumers dealing with cardiovascular risk factors (hypertension, diabetes & obesity), and for general corporate purposes. The Shares or Convertible Debt to be issued in connection with this Offering will be subject to a four month hold period from the share issuance date in accordance with the policies of the Canadian Securities Exchange (CSE) and applicable securities laws. The Offering is subject to all necessary regulatory and stock exchange approvals.

Contact:

Sydney Au, Chairman & CEO
EVITRADE Health Systems Corporation
(formerly Auxellence Health Corporation)

Email: ceo@auxellence.com

Website: <http://www.auxellence.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/auxellence-health-corporation>

About EVITRADE Health Systems Corporation (CSE: EVA, OTCQB: AXHLD)

EVITRADE (formerly Auxellence Health Corp.), was founded in 2013 to provide online services for resolving common health problems.

The company offers a physiologically interactive computing platform that integrates medical devices and artificial intelligence applications into a fully automated, personal health management system for hypertension, arrhythmia, diabetes, and obesity.

The current focus is on the normalization of cardiometabolic power in terms of blood pressure, blood glucose, and body weight – and the monitoring of the physiological response to medical solicitations, mainly medication, diet, exercise, and lifestyle changes.



**EViTRADE
Health
Systems
Corporation**

EVITRADE Health Systems Corporation

About TULIP™

The TULIP™ system is an online self-service intended for adults interested in normalizing blood pressure, heart rate and rhythm, blood glucose, and body weight. Measurement procedures, conditioning protocols, and session schedules are prescribed automatically from data acquired by the user's TULIP™ device – a

blood pressure monitor with interactive protocols that can feed medical records and expert systems useful in testing, tracking and treating common health conditions.

The Tulip™ medical device has received Health Canada and CE Mark certifications.

Disclaimers – Forward Looking Statements

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators which is posted on www.sedar.com, and on <http://thecse.com/en/listings/technology/auxellence-health-corporation>.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.